Uncontrolled hypertension: highlights and perspectives from the European Society of Hypertension Satellite Symposium

Abstract

The Padua ESH 2011 Satellite Symposium on uncontrolled hypertension was focused on why only a relatively small percentage of patients under treatment do not reach ‘safe’ blood pressure levels; the major reason being the modest use of combination therapy. It was also an occasion to discuss new pharmacological and nonpharmacological tools, some of which appear to be efficacious when even the ‘appropriate’ traditional therapeutic strategy fails to work.

Keywords::

• angiotensin antibodies
• baroreceptor stimulation
• combination therapy
• medical inertia
• renal denervation

Financial & competing interests disclosure

AC Pessina and GP Rossi have received sponsorship from AstraZeneca, Bayer Spa, Boehringer Ingelheim, Laboratori Guidotti Spa, Malesci, MSD Italia Srl, Novartis Farma Spa, sanofi-aventis and Sigma Tau Spa to facilitate the organization of this Symposium. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.